Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

Radiotherapy: killing with complement.

Regal JF, Dornfeld KJ, Fleming SD.

Ann Transl Med. 2016 Mar;4(5):94. doi: 10.21037/atm.2015.12.46. No abstract available.

2.

Doxepin rinse versus placebo in the treatment of acute oral mucositis pain in patients receiving head and neck radiotherapy with or without chemotherapy: a phase III, randomized, double-blind trial (NCCTG-N09C6 [Alliance]).

Leenstra JL, Miller RC, Qin R, Martenson JA, Dornfeld KJ, Bearden JD, Puri DR, Stella PJ, Mazurczak MA, Klish MD, Novotny PJ, Foote RL, Loprinzi CL.

J Clin Oncol. 2014 May 20;32(15):1571-7. doi: 10.1200/JCO.2013.53.2630. Epub 2014 Apr 14.

3.

A phase II study of cetuximab and radiation in elderly and/or poor performance status patients with locally advanced non-small-cell lung cancer (N0422).

Jatoi A, Schild SE, Foster N, Henning GT, Dornfeld KJ, Flynn PJ, Fitch TR, Dakhil SR, Rowland KM, Stella PJ, Soori GS, Adjei AA.

Ann Oncol. 2010 Oct;21(10):2040-4. doi: 10.1093/annonc/mdq075. Epub 2010 Jun 21.

4.

Investigation of the pharmacokinetics of 3'-deoxy-3'-[18F]fluorothymidine uptake in the bone marrow before and early after initiation of chemoradiation therapy in head and neck cancer.

Menda Y, Ponto LL, Dornfeld KJ, Tewson TJ, Watkins GL, Gupta AK, Anderson C, McGuire S, Schultz MK, Sunderland JJ, Graham MM, Buatti JM.

Nucl Med Biol. 2010 May;37(4):433-8. doi: 10.1016/j.nucmedbio.2010.02.005.

5.

Kinetic analysis of 3'-deoxy-3'-(18)F-fluorothymidine ((18)F-FLT) in head and neck cancer patients before and early after initiation of chemoradiation therapy.

Menda Y, Boles Ponto LL, Dornfeld KJ, Tewson TJ, Watkins GL, Schultz MK, Sunderland JJ, Graham MM, Buatti JM.

J Nucl Med. 2009 Jul;50(7):1028-35. doi: 10.2967/jnumed.108.058495. Epub 2009 Jun 12.

6.

Cisplatin combined with zidovudine enhances cytotoxicity and oxidative stress in human head and neck cancer cells via a thiol-dependent mechanism.

Mattson DM, Ahmad IM, Dayal D, Parsons AD, Aykin-Burns N, Li L, Orcutt KP, Spitz DR, Dornfeld KJ, Simons AL.

Free Radic Biol Med. 2009 Jan 15;46(2):232-7. doi: 10.1016/j.freeradbiomed.2008.10.023. Epub 2008 Oct 18.

7.
8.

The failure patterns of oral cavity squamous cell carcinoma after intensity-modulated radiotherapy-the university of iowa experience.

Yao M, Chang K, Funk GF, Lu H, Tan H, Wacha J, Dornfeld KJ, Buatti JM.

Int J Radiat Oncol Biol Phys. 2007 Apr 1;67(5):1332-41. Epub 2007 Feb 2.

PMID:
17276613
9.

Changing failure patterns in oropharyngeal squamous cell carcinoma treated with intensity modulated radiotherapy and implications for future research.

Yao M, Nguyen T, Buatti JM, Dornfeld KJ, Tan H, Wacha J, Bayouth JE, Clamon GH, Funk GF, Smith RB, Chang K, Hoffman HT.

Am J Clin Oncol. 2006 Dec;29(6):606-12.

PMID:
17148999
10.

Base excision repair of both uracil and oxidatively damaged bases contribute to thymidine deprivation-induced radiosensitization.

Allen BG, Johnson M, Marsh AE, Dornfeld KJ.

Int J Radiat Oncol Biol Phys. 2006 Aug 1;65(5):1544-52.

PMID:
16863931
11.

Long-term quality of life for surgical and nonsurgical treatment of head and neck cancer.

El-Deiry M, Funk GF, Nalwa S, Karnell LH, Smith RB, Buatti JM, Hoffman HT, Clamon GH, Graham SM, Trask DK, Dornfeld KJ, Yao M.

Arch Otolaryngol Head Neck Surg. 2005 Oct;131(10):879-85.

PMID:
16230590
12.

Intensity-modulated radiation treatment for head-and-neck squamous cell carcinoma--the University of Iowa experience.

Yao M, Dornfeld KJ, Buatti JM, Skwarchuk M, Tan H, Nguyen T, Wacha J, Bayouth JE, Funk GF, Smith RB, Graham SM, Chang K, Hoffman HT.

Int J Radiat Oncol Biol Phys. 2005 Oct 1;63(2):410-21.

PMID:
16168834
13.

Fusion of the HSV-1 tegument protein vp22 to cytosine deaminase confers enhanced bystander effect and increased therapeutic benefit.

Lee KC, Hamstra DA, Bullarayasamudram S, Bhojani MS, Moffat BA, Dornfeld KJ, Ross BD, Rehemtulla A.

Gene Ther. 2006 Jan;13(2):127-37.

PMID:
16163381
14.

The role of FDG PET in management of neck metastasis from head-and-neck cancer after definitive radiation treatment.

Yao M, Smith RB, Graham MM, Hoffman HT, Tan H, Funk GF, Graham SM, Chang K, Dornfeld KJ, Menda Y, Buatti JM.

Int J Radiat Oncol Biol Phys. 2005 Nov 15;63(4):991-9. Epub 2005 Aug 15.

PMID:
16099601
15.

Can post-RT FDG PET accurately predict the pathologic status in neck dissection after radiation for locally advanced head and neck cancer? In regard to Rogers et al. (Int J Radiat Oncol Biol Phys 2004;58:694-697).

Yao M, Buatti JM, Dornfeld KJ, Graham MM, Smith RB, Funk GF, Hoffman HT.

Int J Radiat Oncol Biol Phys. 2005 Jan 1;61(1):306-7; author reply 307. No abstract available.

PMID:
15629631
16.

Value of FDG PET in assessment of treatment response and surveillance in head-and-neck cancer patients after intensity modulated radiation treatment: a preliminary report.

Yao M, Graham MM, Smith RB, Dornfeld KJ, Skwarchuk M, Hoffman HT, Funk GF, Graham SM, Menda Y, Buatti JM.

Int J Radiat Oncol Biol Phys. 2004 Dec 1;60(5):1410-8.

PMID:
15590172
17.

The use of 19F spectroscopy and diffusion-weighted MRI to evaluate differences in gene-dependent enzyme prodrug therapies.

Hamstra DA, Lee KC, Tychewicz JM, Schepkin VD, Moffat BA, Chen M, Dornfeld KJ, Lawrence TS, Chenevert TL, Ross BD, Gelovani JT, Rehemtulla A.

Mol Ther. 2004 Nov;10(5):916-28.

18.

The role of post-radiation therapy FDG PET in prediction of necessity for post-radiation therapy neck dissection in locally advanced head-and-neck squamous cell carcinoma.

Yao M, Graham MM, Hoffman HT, Smith RB, Funk GF, Graham SM, Dornfeld KJ, Skwarchuk M, Menda Y, Buatti JM.

Int J Radiat Oncol Biol Phys. 2004 Jul 15;59(4):1001-10.

PMID:
15234033
19.

In regard to Lee et al. Intensity-modulated radiation therapy for head-and-neck cancer: the UCSF experience focusing on target volume delineation. (Int J Radiat Oncol Biol Phys 2003;57:49-60).

Yao M, Dornfeld KJ, Buatti JM.

Int J Radiat Oncol Biol Phys. 2004 Apr 1;58(5):1639; author reply 1639-40. No abstract available.

PMID:
15050350
20.

Ex vivo gene therapy for skeletal regeneration in cranial defects compromised by postoperative radiotherapy.

Nussenbaum B, Rutherford RB, Teknos TN, Dornfeld KJ, Krebsbach PH.

Hum Gene Ther. 2003 Jul 20;14(11):1107-15.

21.

The potential of 5-fluorocytosine/cytosine deaminase enzyme prodrug gene therapy in an intrahepatic colon cancer model.

Nyati MK, Symon Z, Kievit E, Dornfeld KJ, Rynkiewicz SD, Ross BD, Rehemtulla A, Lawrence TS.

Gene Ther. 2002 Jul;9(13):844-9.

22.

A predisposition supposition for glioma.

Dornfeld KJ, Lawrence TS.

J Natl Cancer Inst. 2001 Oct 17;93(20):1512-3. No abstract available.

PMID:
11604467
23.

Increased spontaneous mutation frequency in human cells expressing the phage PBS2-encoded inhibitor of uracil-DNA glycosylase.

Radany EH, Dornfeld KJ, Sanderson RJ, Savage MK, Majumdar A, Seidman MM, Mosbaugh DW.

Mutat Res. 2000 Sep 15;461(1):41-58.

PMID:
10980411
24.

Pituitary irradiation is ineffective in normalizing plasma insulin-like growth factor I in patients with acromegaly.

Barkan AL, Halasz I, Dornfeld KJ, Jaffe CA, Friberg RD, Chandler WF, Sandler HM.

J Clin Endocrinol Metab. 1997 Oct;82(10):3187-91.

PMID:
9329336
25.

Plasmid recombination in a rad52 mutant of Saccharomyces cerevisiae.

Dornfeld KJ, Livingston DM.

Genetics. 1992 Jun;131(2):261-76.

26.
27.

Effect of limited homology on gene conversion in a Saccharomyces cerevisiae plasmid recombination system.

Ahn BY, Dornfeld KJ, Fagrelius TJ, Livingston DM.

Mol Cell Biol. 1988 Jun;8(6):2442-8.

Supplemental Content

Loading ...
Support Center